Lastly, to determine whether depletion of mutant IDH sensitizes chondrosarcoma cells to specific compounds for potential combination therapies with mutant IDH inhibitors, we conducted a drug sensitivity analysis of mutant IDH1 KO cells and compared their responses to those of parental cells. Here, IDH2 is linked to chondrosarcoma.